MoonLake Immunotherapeutics
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLTX research report →
Range $34 – $50
Price Chart
About the company
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis.
- CEO
- Jorge Santos da Silva
- IPO
- 2020
- Employees
- 130
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on MLTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $942.13M
- P/E
- -3.00
- Fwd P/E
- 4.88
- PEG
- 0.27
- P/S
- 0.00
- P/B
- 2.47
- EV/EBITDA
- -2.55
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -79.95%
- ROIC
- -57.27%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,616,000+0.0%
- Op Income
- $-244,834,000
- Net Income
- $-227,318,000-91.1%
- EPS
- $-3.53-86.8%
- OCF Growth
- -68.1%
- FCF Growth
- -67.4%
- 52W High
- $23.29
- 52W Low
- $9.46
- 50D MA
- $11.64
- 200D MA
- $16.17
- Beta
- 1.13
- RSI (14)
- 44
- Avg Volume
- 1.64M
No earnings-call transcripts are available for MLTX yet.
- Free Float
- 88.3%
- Shares Outstanding
- 85.11M
- Float Shares
- 75.12M
of shares held by institutions
187 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 16.00M | 0 |
| Deep Track Capital, LP | 8.11M | ▲ 1.11M |
| T. Rowe Price Investment Management, Inc. | 5.22M | ▲ 939.22K |
| D. E. Shaw & Co., Inc. | 3.49M | ▲ 121.73K |
| Jupiter Topco LLC | 3.09M | ▲ 3.09M |
| Cormorant Asset Management, LP | 2.86M | ▼ 350.00K |
| Weiss Asset Management LP | 2.34M | ▼ 240.72K |
| Two Sigma Investments, LP | 1.98M | ▲ 260.99K |
| Jpmorgan Chase & Co | 1.89M | ▲ 505.07K |
| Qube Research & Technologies Ltd | 1.80M | ▲ 1.30M |
| Renaissance Technologies LLC | 1.72M | ▲ 1.07M |
| Citadel Advisors LLC | 1.71M | ▼ 267.13K |
Held by 75 ETFs
Biggest fund positions in MLTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | Reich Kristian | sell | 1,100 |
| Jul 21, 26 | Reich Kristian | sell | 50,000 |
| Jul 22, 26 | Reich Kristian | sell | 2,448 |
| Jul 20, 26 | Reich Kristian | sell | 43,700 |
| Jul 15, 26 | Reich Kristian | sell | 16,105 |
| Jul 9, 26 | Santos da Silva Jorge | sell | 33,936 |
| Jul 10, 26 | Santos da Silva Jorge | sell | 68,289 |
| Jul 1, 26 | Santos da Silva Jorge | sell | 47,775 |
| Jun 22, 26 | Bodenstedt Matthias | sell | 39,120 |
| Jun 17, 26 | BVF PARTNERS L P/IL | other | 22,195 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MLTX coverage
Recent articles, reports, and earnings notes.
No research on MLTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLTX report →MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com · Nov 4
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
benzinga.com · Oct 22
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
seekingalpha.com · Sep 8
MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
defenseworld.net · Aug 11
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
reuters.com · Aug 10
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 10
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
defenseworld.net · Aug 6
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
zacks.com · Jul 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.